Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26626023 | 0.86 | ARG1 (0.33) | UGT2B7 | |
| SCHEMBL25554787 | 0.83 | ESR2 (0.35) | ESR2UGT2B7BRD4 | |
| SCHEMBL2703732 | 0.79 | APLNR (0.36) | ESR2 | |
| SCHEMBL19012099 | 0.77 | CYP1A2 (0.37) | — | |
| SCHEMBL21066 | 0.75 | APLNR (0.39) | ESR2 | |
| SCHEMBL3835776 | 0.75 | CYP1A2 (0.46) | — | |
| SCHEMBL6654496 | 0.75 | — | — | |
| SCHEMBL6485088 | 0.75 | — | — | |
| SCHEMBL7963544 | 0.75 | ESR2 (0.32) | ESR2 | |
| SCHEMBL24197652 | 0.74 | ESR2 (0.50) | ESR2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3059239-B1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2018-06-27 | — | — | EP | disclosed |
| CN-105636965-B | The ring type compound of sulfur-bearing two | 安斯泰来制药株式会社 | 2017-11-24 | — | — | CN | disclosed |
| US-9642852-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-05-09 | — | — | US | disclosed |
| EP-3059239-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2016-08-24 | — | — | EP | disclosed |
| CN-105636965-A | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC | 2016-06-01 | — | — | CN | disclosed |
| US-20150231138-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
| US-9051339-B2 | Sulfur-containing bicyclic compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20150111876-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-6958402-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. (US) | 2004-12-16 | — | — | US | disclosed |
| EP-1467731-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2004-10-20 | — | — | EP | disclosed |
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6713496-B2 | 3-(imidazolyl)-2-alkoxypropanoic acids | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2003061652-A1 | 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1077940-A1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059971-A1 | NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199522-A1 | 3-(Imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | ESR2 999/4885UGT2B7 529/4885BRD4 3347/4885 |
| US-20150111876-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | GABRB1, GABRA1, GABBR1 | ESR2 2549/4885UGT2B7 1796/4885BRD4 418/4885 |
| US-20040254164-A1 | 3-(imidazolyl)-2-alkoxypropanoic acids | F2, FGB, F7 | ESR2 1022/4885UGT2B7 546/4885BRD4 3293/4885 |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | ESR2 901/4885UGT2B7 376/4885BRD4 517/4885 |
| US-20150231138-A1 | SULFUR-CONTAINING BICYCLIC COMPOUND | GABBR1, GABRB1, GRIN2C | ESR2 2768/4885UGT2B7 1887/4885BRD4 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.